Deciphera Pharmaceuticals Inc., of Waltham, Mass., said it priced its registered underwritten public offering of 10.81 million shares of its common stock at $37 each. The gross proceeds are expected to be $400 million, with the underwriters being granted a 30-day option to purchase up to 1.62 million additional shares.